Eli Lilly And Company ((LLY)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company, in collaboration with AstraZeneca, is conducting a Phase 3 clinical trial titled A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer – SUNRAY-02. The study aims to evaluate the effectiveness of olomorasib combined with standard immunotherapy compared to placebo in treating KRAS G12C-mutant non-small cell lung cancer (NSCLC), a significant advancement in targeting this specific mutation.
Intervention/Treatment: The study tests olomorasib, an oral drug, in combination with pembrolizumab and durvalumab, both administered intravenously. These combinations aim to enhance treatment efficacy for patients with resected and unresectable KRAS G12C-mutant NSCLC.
Study Design: This interventional study is randomized and double-blind, involving both participants and investigators. It follows a parallel assignment model with the primary purpose of treatment, ensuring rigorous testing of the drug combinations against placebo.
Study Timeline: The study began on March 27, 2025, with recruitment currently ongoing. The last update was submitted on July 22, 2025. These dates are crucial as they mark the progress and current status of the trial, indicating active engagement in the study.
Market Implications: The successful outcome of this trial could significantly impact Eli Lilly and AstraZeneca’s stock performance, boosting investor confidence due to the potential introduction of a new treatment for KRAS G12C-mutant NSCLC. This development could position these companies favorably against competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.